GLI1 and colorectal cancer: A phase I trial investigating the co-administration of ATO and 5-Fluorouracil/Leucovorin in patients with advanced/relapsed colorectal cancer showed that ATO was well tolerated and that in some patients it was associated with down-regulated thymidylate synthase expression, indicating a therapeutic response, and increased survival39; a later study investigated GLI1 levels in biopsies from the said clinical trial and found that it resulted to be down modulated after ATO administration40.